EP1043973A1 - Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant - Google Patents

Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant

Info

Publication number
EP1043973A1
EP1043973A1 EP98964662A EP98964662A EP1043973A1 EP 1043973 A1 EP1043973 A1 EP 1043973A1 EP 98964662 A EP98964662 A EP 98964662A EP 98964662 A EP98964662 A EP 98964662A EP 1043973 A1 EP1043973 A1 EP 1043973A1
Authority
EP
European Patent Office
Prior art keywords
surfactant
glucocorticosteroid
micelles
composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98964662A
Other languages
German (de)
French (fr)
Inventor
Gabrielle Sjöquist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1043973A1 publication Critical patent/EP1043973A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant
  • the invention further relates to a process for the preparation of the pharmaceutical composition and use of the pharmaceutical composition for the manufacture of a medicament for treating allergic and/or infla - matory diseases in the respiratory tract or for treating intestinal diseases and methods for treatment of the diseases in a mammal, including man.
  • Rhinitis and asthma are today effectively treated by the use of glucocorticosteroids such as e.g. mometasone furoate, budesonide, and fluticasone propionate.
  • glucocorticosteroids such as e.g. mometasone furoate, budesonide, and fluticasone propionate.
  • Patent applications that can be mentioned in this context are WO 92/13873 and WO 96/19199 both to Astra AB of Sweden.
  • the glucocorticosteroid compositions are used in the form of powders in dry powder inhalers, as solutions or suspensions in pressurized metered dose inhalers (pMDIs).
  • pMDIs pressurized metered dose inhalers
  • a suspension in water is a user-friendly form of administration as the solution is easily accepted by the mucosa.
  • the glucocorticosteroid crystals are in contact with the water which can affect the stability of the glucocorticosteroid.
  • a glucocorticosteroid ester may be chemically degraded for example by ester hydrolysis when using such a compound.
  • the compositions in the form of suspensions may be less stable than solutions e.g.
  • compositions for trans- mucosal membrane administration of protein or peptide drugs wherein the compositions comprise the drug in mixtures with at least one bile salt or fusidate or a derivative thereof and at least one non-ionic detergent of the formula RO(CHR'CH 2 O) n R, wherein one R is H and the other R represents the radical of a saturated or unsaturated cyclic or acyclic organic alcohol of 6-40 carbons.
  • EP 0179583 Al to Merck & Co. Inc. discloses a system for enhancing the water dissolution rate and solubility of poorly soluble drugs.
  • the compositions of EP 0179583 Al involve combining the poorly water-soluble drug with the surfactant in appropriate ratios and by an appropriate method that results in the formation of an anhydrous product.
  • the examples are directed to anhydrous compositions of the antiparasitic agents ivermectin or abamectin and a surfactant.
  • IBD inflammatory bowel diseases
  • a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocortico- steroid and one and only one pharmaceutically acceptable surfactant.
  • the composition comprises one and only one non- ionic surfactant.
  • composition is used for treating allergic and/or inflammatory diseases in the respiratory tract.
  • composition is used for treating intestinal diseases.
  • a process for the preparation of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, the process comprising the steps of: a) dissolving the glucocorticosteroid in the surfactant; b) adding an aqueous medium to the solution from step a) and stirring the solution.
  • composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, for the manufacture of a medicament for treating allergic and inflammatory diseases in the respiratory tract is obtained.
  • composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant for the manufacture of a medicament for treating intestinal diseases is obtained.
  • Another aspect of the invention is a method for treatment of allergic and/or inflammatory diseases in the respiratory tract of a mammal, including man.
  • the method is characterized by administration to the mammal in need of such treatment of an therapeutically effective amount of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant.
  • a last aspect of the invention is a method for treatment of intestinal diseases in a mammal, including man.
  • the method is characterized by administration to the mammal in need of such treatment of an therapeutically effective amount of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant.
  • lipophilic glucocorticosteroids and their esters can be incorporated in micelles formed by a surfactant, especially a non-ionic surfactant, in an aqueous medium.
  • a surfactant especially a non-ionic surfactant
  • micelles are molecular aggregates formed in the solution of a surfactant.
  • Surfactants in a dilute aqueous solution exist primarily as monomers, but at higher concentrations a number of surfactant molecules aggregate to form micelles. Thereby a stable formulation is obtained in which the lipophilic glucocorticosteroid/glucocorticosteroid ester is protected and is possible to be absorbed.
  • the micelles will act as non-aqueous reservoirs for the lipophilic glucocorticosteroid and will positively affect the pharmacokinetic and deposition of the glucocorticosteroid molecule.
  • the glucocorticosteroid will also be more easy to dose accurately as well as for the patient to administer accurately.
  • lipophilic reference can be made to the above mentioned reference where on p. 155 it is stated that "lipophilic drugs may be wetted by oils and semipolar liquids.”
  • compositions comprising the lipophilic glucocorticosteroids used in the invention in an aqueous medium are very difficult to dissolve in water and then to obtain a stable composition. It was found in the present invention that by dissolving the lipophilic glucocorticosteroid in a surfactant, preferably a non-ionic surfactant, stable compositions can be obtained with the glucocorticosteroid in micellar form.
  • a surfactant preferably a non-ionic surfactant
  • the inventor of the present invention has further found that use of the stable compositions comprising e.g. rofleponide palmitate incorporated in micelles formed by a surfactant, causes less irritation in the lung after oral inhalation by human patients, than is experienced after oral inhalation of the same surfactant on its own.
  • the present compositions comprise one and only one surfactant.
  • the surfactant used in the present compositions can be non-ionic, zwitterionic, anionic or cationic. It is, however, preferred, to use a non-ionic surfactant, since this normally reduces the risk of side-effects after administration. Examples of non-ionic, zwitterionic, anionic or cationic surfactants which may be used in the present invention can be found in Wade and Weller, Handbook of Pharmaceutical Excipients, 1994, The Pharmaceutical Press, London.
  • the non-ionic surfactants used according to the present invention are suitably selected from poloxamers, e.g. poloxamer 188; polyoxyethylene alkyl ethers, e.g.poloxyl 10 stearyl ether, poloxyl 20 stearyl ether; polyoxyethylene stearates, e.g. polyoxyl 8 stearate, poloxyl 12 stearate; polyoxyethyleneglycolhydroxystearates, e.g. polyoxyethyleneglycol 12- hydroxystearates, and polyoxyethylene sorbitan fatty acid esters.
  • a preferred group of non- ionic surfactants is polyoxyethylene sorbitan fatty acid esters, e.g.
  • polyoxyethylene 20 sorbitan monolaurate, monopalmitate, monostearate or monooleate also known as poly- sorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80, respectively
  • suitable commercial polysorbates are Tween 20, Tween 40, Tween 60 and Tween 80.
  • a further preferred group of non-ionic surfactants is polyoxyethyleneglycol 12-hydroxy- stearates and an especially preferred compound is polyoxyethyleneglycol 660 12-hydroxy- stearate.
  • lipophilic glucocorticosteroids relate to lipophilic glucocorticosteroids per se, as well as their pharmaceutically acceptable solvates, esters, acetals and salts, and solvates of any of these.
  • glucocorticosteroids examples include betamethasone, fluticasone (e.g. as propionate), budesonide, tipredane, dexamethasone, beclomethasone (e.g. as dipropionate), prednisolone, fluocinolone (e.g. as acetonide), triamcinolone (e.g. as acetonide), mometasone (e.g. as furoate), rofleponide (e.g.
  • mometasone furoate beclomethasone dipropionate or fluticasone propionate or glucocorticosteroids with an asymmetric acetal structure, e.g. comprising 16 ⁇ ,17 ⁇ -butylidenedioxy group, such as budesonide or rofleponide or pharmaceutically acceptable solvates, esters, acetals or salts, or where applicable, solvates thereof.
  • the most preferred lipophilic glucocorticosteroid ester is rofleponide palmitate.
  • the amount of surfactant used in the composition should be less than 5 % (w/w) of the total composition weight.
  • the amount of surfactant is less than 3 % (w/w) and most preferably less than 1 % (w/w) of the total composition weight.
  • the concentration of the surfactant must, however, be higher than the critical micellar concentration (CMC), being the lowest concentration at which micelles are formed in an aqueous medium.
  • CMC critical micellar concentration
  • the CMC value depends primarily upon the temperature and the concentration of possible additives. It lies within the competence of the skilled person to determine the CMC for each indivi-dual composition and thus prepare suitable micelles according to the present invention.
  • the amount of the glucocorticosteroid used depends on the field of use. If the glucocorticosteroid is used for treating diseases in the respiratory tract by inhalation a suitable daily dose is from 10 to 2400 ⁇ g, preferably from 10 to 1600 ⁇ g. If the glucocorticosteroid is used for treating intestinal diseases a suitable daily dose is from 400 to 4000 ⁇ g, preferably from 800 to 3000 ⁇ g.
  • composition according to the invention may also contain one or more pharmaceutically acceptable additives such as buffers and other pH modifiers, antioxidants, complexing agents to further increase the stability, viscosity regulating agents andisotonicity modifying agents.
  • pharmaceutically acceptable additives such as buffers and other pH modifiers, antioxidants, complexing agents to further increase the stability, viscosity regulating agents andisotonicity modifying agents.
  • Compounds used as such agents are compounds generally used in drug formulations e.g. EDTA for complexing and carboxymethyl cellulose (CMC) for regulating viscosity.
  • substances for adjusting the isotonicity can be mentioned glucose, mannitol, salts, glycerol and propylene-glycol.
  • alkaline buffers are used such that the pH of the composition is from 4 to 7. It is, however, preferred to use one or more antioxidants), which may be water-soluble to a smaller or larger degree.
  • antioxidants include, without limitation, tocopherols, especially ⁇ -tocopherol, and preferably racemic ⁇ -tocopherol, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT) and ascorbic acid.
  • BHA butylhydroxyanisole
  • BHT butylhydroxytoluene
  • ascorbic acid ascorbic acid
  • the aqueous medium is added to the glucocorticosteroid- surfactant solution and the mixture is stirred, preferably intensely stirred, to obtain a stable and homogeneous solution.
  • the aqueous medium is of the same temperature as the one of the glucocorticosteroid-surfactant solution before it is added to the solution. If other pharmaceutically acceptable additives are used they are suitably added to the aqueous medium before mixing with the glucocorticosteroid-surfactant solution if they are water soluble. Otherwise they are added to the surfactant solution.
  • glucose is dissolved in the aqueous medium in an isotonic amount.
  • the surfactant used can be a solid compound at ambient temperature or a more or less fluid compound. If a solid surfactant is used it should be heated in order to melt it in a first step of the process. The glucocorticosteroid is then dissolved in the melted surfactant. This is a preferred embodiment of the invention.
  • the glucocorticosteroid can be dissolved directly in the surfactant at ambient temperature or it may be suitable to increase the temperature of the surfactant to more readily dissolve the glucocorticosteroid. Then the water is added.
  • a further possibility is to dissolve the surfactant in a conventional organic solvent, e.g. ethanol, and then to dissolve the glucocorticosteroid in this solution or vice versa.
  • the organic solvent then has to be evaporated before the aqueous medium is added. It is impor- tant that the organic solvent is removed from the composition otherwise the composition will have a stinging effect in the nose of the patient if the composition is used for the manufacture of a medicament for treating allergic and/or inflammatory diseases in the respiratory tract.
  • the composition according to the invention can be made sterile in a conventional manner, e.g. by using dry heat, steam or irradiation.
  • the composition according to the invention is used for the manufacture of a medicament for treating allergic and/or inflammatory diseases in the respiratory tract.
  • the composition can then be administered via the upper and lower respiratory tract, including nasal or oral inhalation.
  • the composition according to the invention can be used in common devices for aqueous solutions for nasal and oral inhalation e.g. in a spray pump or in a nebulizer.
  • nebulisation reference is made to "Medication Nebulizer Performance", Chest 1 10(2), (1996), pp. 498-505.
  • the composition according to the invention is also used for the manufacture of a medicament for treating intestinal diseases such as inflammatory bowel diseases (IBD), ulcerative colitis and Crohn's disease.
  • the compositions can then be administered by rectal administration.
  • the invention also relates to a method for treatment of allergic and/or inflammatory diseases in the respiratory tract of a mammal, including man.
  • the composition according to the invention is administered in a therapeutically effective amount to the mammal in need of such a treatment, preferably by nasal or oral inhalation.
  • the invention also relates to a method of treatment of intestinal diseases in a mammal, including man.
  • the composition according to the invention is administered in a therapeutically effective amount to the mammal in need of such a treatment, preferably by rectal administration.
  • Solutol® HS 15 polyethyleneglycol 660 12-hydroxystearate manufactured by BASF of Germany is melted in a beaker at 35°C-40°C. 100 mg rofleponide palmitate is added to the melt and dissolved.

Abstract

The present invention relates to a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant. The invention further relates to a process for the preparation of the pharmaceutical composition and use of the pharmaceutical composition for the manufacture of a medicament for treating allergic and/or inflammatory diseases in the respiratory tract or for treating intestinal diseases and methods for treatment of the diseases in a mammal, including man.

Description

PHARMACEUTICAL COMPOSITIONS COMPRISING MICELLES COMPRISING LIPOPHILIC GLUCOCORTICOSTEROID AND ONLY ONE SURFACTANT
FIELD OF INVENTION
The present invention relates to a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant The invention further relates to a process for the preparation of the pharmaceutical composition and use of the pharmaceutical composition for the manufacture of a medicament for treating allergic and/or infla - matory diseases in the respiratory tract or for treating intestinal diseases and methods for treatment of the diseases in a mammal, including man.
BACKGROUND OF THE INVENTION
Rhinitis and asthma are today effectively treated by the use of glucocorticosteroids such as e.g. mometasone furoate, budesonide, and fluticasone propionate. Patent applications that can be mentioned in this context are WO 92/13873 and WO 96/19199 both to Astra AB of Sweden.
Well-known methods of administering the glucocorticosteroids are by oral and nasal inhalation. The glucocorticosteroid compositions are used in the form of powders in dry powder inhalers, as solutions or suspensions in pressurized metered dose inhalers (pMDIs). A suspension in water is a user-friendly form of administration as the solution is easily accepted by the mucosa. However, in a water suspension the glucocorticosteroid crystals are in contact with the water which can affect the stability of the glucocorticosteroid. A glucocorticosteroid ester may be chemically degraded for example by ester hydrolysis when using such a compound. Further, the compositions in the form of suspensions may be less stable than solutions e.g. due to sedimentation or precipitation. It is also easier to administer a solution accurately in comparison with a suspension. US 4,994,439 to California Biotechnology discloses aqueous compositions for trans- mucosal membrane administration of protein or peptide drugs wherein the compositions comprise the drug in mixtures with at least one bile salt or fusidate or a derivative thereof and at least one non-ionic detergent of the formula RO(CHR'CH2O)nR, wherein one R is H and the other R represents the radical of a saturated or unsaturated cyclic or acyclic organic alcohol of 6-40 carbons. The use of a mixture of carrier components results in the formation of mixed micelles, exhibiting transport efficiencies across mucous membranes comparable to or better than those achieved using bile salts/fusidates alone. Detergents on their own are said to be poor absorption promoters.
EP 0179583 Al to Merck & Co. Inc. discloses a system for enhancing the water dissolution rate and solubility of poorly soluble drugs. The compositions of EP 0179583 Al involve combining the poorly water-soluble drug with the surfactant in appropriate ratios and by an appropriate method that results in the formation of an anhydrous product. The examples are directed to anhydrous compositions of the antiparasitic agents ivermectin or abamectin and a surfactant.
It is an object of the present invention to provide a stable aqueous solution of a lipophilic glucocorticosteroid for use as a medicament, especially for treating allergic and/or inflam- matory diseases in the respiratory tract and also for treating intestinal diseases such as inflammatory bowel diseases (IBD), ulcerative colitis and Crohn's disease.
It is a further object of the invention to provide a process for the preparation of such a stable solution. SUMMARY OF THE INVENTION
According to the invention there is provided a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocortico- steroid and one and only one pharmaceutically acceptable surfactant.
According to a preferred embodiment the composition comprises one and only one non- ionic surfactant.
According to another preferred embodiment the composition is used for treating allergic and/or inflammatory diseases in the respiratory tract.
According to yet another preferred embodiment the composition is used for treating intestinal diseases.
According to a further aspect of the invention a process for the preparation of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, the process comprising the steps of: a) dissolving the glucocorticosteroid in the surfactant; b) adding an aqueous medium to the solution from step a) and stirring the solution.
According to yet another aspect of the invention use of a composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, for the manufacture of a medicament for treating allergic and inflammatory diseases in the respiratory tract is obtained.
According to a further aspect of the invention use of a composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant for the manufacture of a medicament for treating intestinal diseases is obtained.
Another aspect of the invention is a method for treatment of allergic and/or inflammatory diseases in the respiratory tract of a mammal, including man. The method is characterized by administration to the mammal in need of such treatment of an therapeutically effective amount of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant.
A last aspect of the invention is a method for treatment of intestinal diseases in a mammal, including man. The method is characterized by administration to the mammal in need of such treatment of an therapeutically effective amount of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant.
DETAILED DESCRIPTION OF THE INVENTION
According to d e present invention it was found that lipophilic glucocorticosteroids and their esters can be incorporated in micelles formed by a surfactant, especially a non-ionic surfactant, in an aqueous medium. According to "Pharmaceutical Dosage Forms; Disperse Systems", vol.l, p.315 ff (1988) ed. by H.A. Lieberman et al, micelles are molecular aggregates formed in the solution of a surfactant. Surfactants in a dilute aqueous solution exist primarily as monomers, but at higher concentrations a number of surfactant molecules aggregate to form micelles. Thereby a stable formulation is obtained in which the lipophilic glucocorticosteroid/glucocorticosteroid ester is protected and is possible to be absorbed.
The micelles will act as non-aqueous reservoirs for the lipophilic glucocorticosteroid and will positively affect the pharmacokinetic and deposition of the glucocorticosteroid molecule. The glucocorticosteroid will also be more easy to dose accurately as well as for the patient to administer accurately. For further information of the expression "lipophilic" reference can be made to the above mentioned reference where on p. 155 it is stated that "lipophilic drugs may be wetted by oils and semipolar liquids."
The problem with preparation of compositions comprising the lipophilic glucocorticosteroids used in the invention in an aqueous medium is that they are very difficult to dissolve in water and then to obtain a stable composition. It was found in the present invention that by dissolving the lipophilic glucocorticosteroid in a surfactant, preferably a non-ionic surfactant, stable compositions can be obtained with the glucocorticosteroid in micellar form.
The inventor of the present invention, has further found that use of the stable compositions comprising e.g. rofleponide palmitate incorporated in micelles formed by a surfactant, causes less irritation in the lung after oral inhalation by human patients, than is experienced after oral inhalation of the same surfactant on its own.
The present compositions comprise one and only one surfactant. The surfactant used in the present compositions can be non-ionic, zwitterionic, anionic or cationic. It is, however, preferred, to use a non-ionic surfactant, since this normally reduces the risk of side-effects after administration. Examples of non-ionic, zwitterionic, anionic or cationic surfactants which may be used in the present invention can be found in Wade and Weller, Handbook of Pharmaceutical Excipients, 1994, The Pharmaceutical Press, London.
The non-ionic surfactants used according to the present invention are suitably selected from poloxamers, e.g. poloxamer 188; polyoxyethylene alkyl ethers, e.g.poloxyl 10 stearyl ether, poloxyl 20 stearyl ether; polyoxyethylene stearates, e.g. polyoxyl 8 stearate, poloxyl 12 stearate; polyoxyethyleneglycolhydroxystearates, e.g. polyoxyethyleneglycol 12- hydroxystearates, and polyoxyethylene sorbitan fatty acid esters. A preferred group of non- ionic surfactants is polyoxyethylene sorbitan fatty acid esters, e.g. polyoxyethylene 20 sorbitan monolaurate, monopalmitate, monostearate or monooleate also known as poly- sorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80, respectively Examples of suitable commercial polysorbates are Tween 20, Tween 40, Tween 60 and Tween 80.
A further preferred group of non-ionic surfactants is polyoxyethyleneglycol 12-hydroxy- stearates and an especially preferred compound is polyoxyethyleneglycol 660 12-hydroxy- stearate.
In the present invention, lipophilic glucocorticosteroids relate to lipophilic glucocorticosteroids per se, as well as their pharmaceutically acceptable solvates, esters, acetals and salts, and solvates of any of these.
Examples of glucocorticosteroids which may be used in the present invention include betamethasone, fluticasone (e.g. as propionate), budesonide, tipredane, dexamethasone, beclomethasone (e.g. as dipropionate), prednisolone, fluocinolone (e.g. as acetonide), triamcinolone (e.g. as acetonide), mometasone (e.g. as furoate), rofleponide (e.g. as palmitate), flumethasone, flunisolide, ciclesonide, deflazacort, cortivazol, 16α,17α- butylidenedioxy-6α,9α-difluoro- 11 β,21 -dihydroxy-pregna- 1 ,4-diene-3,20-dione; 6α,9α- difluoro- 11 β-hydroxy- 16α, 17α-butylidenedioxy- 17β-methylthio-androsta-4-ene-3-one; 16α, 17α-butylidenedioxy-6α,9α-difluoro- 11 β-hydroxy-3-oxo-androsta- 1 ,4-diene- 17β- carbothioic acid S-methyl ester; methyl 9α-chloro-6 -fluoro- 11 β-hydroxy- 16α-methyl-3- oxo- 17α-propionyloxy-androsta- 1 ,4-diene- 17α-carboxylate; 6α,9α-difluoro- 1 1 β-hydroxy- 16α-methyl-3-oxo-17α-propionyloxy-androsta-l,4-diene-17β-carbothioic acid S-(2-oxo- tetrahydrofuran-3-yl) ester; optionally in their pure isomeric forms (where such forms exist) and/or in the form of their pharmaceutically acceptable solvates, esters, acetals or salts, or where applicable solvates of any of these. Suitably, use is made of mometasone furoate, beclomethasone dipropionate or fluticasone propionate or glucocorticosteroids with an asymmetric acetal structure, e.g. comprising 16α,17α-butylidenedioxy group, such as budesonide or rofleponide or pharmaceutically acceptable solvates, esters, acetals or salts, or where applicable, solvates thereof. The most preferred lipophilic glucocorticosteroid ester is rofleponide palmitate. The amount of surfactant used in the composition should be less than 5 % (w/w) of the total composition weight. Preferably the amount of surfactant is less than 3 % (w/w) and most preferably less than 1 % (w/w) of the total composition weight. The concentration of the surfactant must, however, be higher than the critical micellar concentration (CMC), being the lowest concentration at which micelles are formed in an aqueous medium. The CMC value depends primarily upon the temperature and the concentration of possible additives. It lies within the competence of the skilled person to determine the CMC for each indivi-dual composition and thus prepare suitable micelles according to the present invention.
The amount of the glucocorticosteroid used depends on the field of use. If the glucocorticosteroid is used for treating diseases in the respiratory tract by inhalation a suitable daily dose is from 10 to 2400 μg, preferably from 10 to 1600 μg. If the glucocorticosteroid is used for treating intestinal diseases a suitable daily dose is from 400 to 4000 μg, preferably from 800 to 3000 μg.
The composition according to the invention may also contain one or more pharmaceutically acceptable additives such as buffers and other pH modifiers, antioxidants, complexing agents to further increase the stability, viscosity regulating agents andisotonicity modifying agents. Compounds used as such agents are compounds generally used in drug formulations e.g. EDTA for complexing and carboxymethyl cellulose (CMC) for regulating viscosity. As substances for adjusting the isotonicity can be mentioned glucose, mannitol, salts, glycerol and propylene-glycol. Preferably alkaline buffers are used such that the pH of the composition is from 4 to 7. It is, however, preferred to use one or more antioxidants), which may be water-soluble to a smaller or larger degree. Examples of such antioxidants include, without limitation, tocopherols, especially α-tocopherol, and preferably racemic α-tocopherol, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT) and ascorbic acid. In order to prepare the aqueous composition according to the present invention the glucocorticosteroid drug has to be dissolved in a first step. It was found in the present invention that a stable composition of the glucocorticosteroid is obtained if the glucocorticosteroid is dissolved in the surfactant. Then the aqueous medium is added to the glucocorticosteroid- surfactant solution and the mixture is stirred, preferably intensely stirred, to obtain a stable and homogeneous solution. Preferably the aqueous medium is of the same temperature as the one of the glucocorticosteroid-surfactant solution before it is added to the solution. If other pharmaceutically acceptable additives are used they are suitably added to the aqueous medium before mixing with the glucocorticosteroid-surfactant solution if they are water soluble. Otherwise they are added to the surfactant solution. In a preferred embodiment of the process glucose is dissolved in the aqueous medium in an isotonic amount.
The surfactant used can be a solid compound at ambient temperature or a more or less fluid compound. If a solid surfactant is used it should be heated in order to melt it in a first step of the process. The glucocorticosteroid is then dissolved in the melted surfactant. This is a preferred embodiment of the invention.
If the surfactant is fluid enough the glucocorticosteroid can be dissolved directly in the surfactant at ambient temperature or it may be suitable to increase the temperature of the surfactant to more readily dissolve the glucocorticosteroid. Then the water is added.
A further possibility is to dissolve the surfactant in a conventional organic solvent, e.g. ethanol, and then to dissolve the glucocorticosteroid in this solution or vice versa. The organic solvent then has to be evaporated before the aqueous medium is added. It is impor- tant that the organic solvent is removed from the composition otherwise the composition will have a stinging effect in the nose of the patient if the composition is used for the manufacture of a medicament for treating allergic and/or inflammatory diseases in the respiratory tract. Optionally the composition according to the invention can be made sterile in a conventional manner, e.g. by using dry heat, steam or irradiation.
The composition according to the invention is used for the manufacture of a medicament for treating allergic and/or inflammatory diseases in the respiratory tract. The composition can then be administered via the upper and lower respiratory tract, including nasal or oral inhalation. The composition according to the invention can be used in common devices for aqueous solutions for nasal and oral inhalation e.g. in a spray pump or in a nebulizer. For administration by nebulisation reference is made to "Medication Nebulizer Performance", Chest 1 10(2), (1996), pp. 498-505. The composition according to the invention is also used for the manufacture of a medicament for treating intestinal diseases such as inflammatory bowel diseases (IBD), ulcerative colitis and Crohn's disease. The compositions can then be administered by rectal administration.
The invention also relates to a method for treatment of allergic and/or inflammatory diseases in the respiratory tract of a mammal, including man. The composition according to the invention is administered in a therapeutically effective amount to the mammal in need of such a treatment, preferably by nasal or oral inhalation.
The invention also relates to a method of treatment of intestinal diseases in a mammal, including man. The composition according to the invention is administered in a therapeutically effective amount to the mammal in need of such a treatment, preferably by rectal administration.
The invention will now be illustrated by the following non-limiting example: EXAMPLE
Manufacturing of rofleponide palmitate in micellar solution.
5 g Solutol® HS 15 (polyethyleneglycol 660 12-hydroxystearate) manufactured by BASF of Germany is melted in a beaker at 35°C-40°C. 100 mg rofleponide palmitate is added to the melt and dissolved.
An isotonic solution of 25 g glucose in 495 g water is heated to 35-40°C and added to the melt using intense stirring. A clear solution containing 0.2 mg rofleponide palmitate/ml is obtained.

Claims

1. A pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant.
2. The composition according to claim 1 or 2, wherein the surfactant is a non-ionic surfactant.
3. The composition according to claim 2, wherein said non-ionic surfactant is selected from the group consisting of poloxamers, polyoxyethylene alkyl ethers, polyoxyethylene stearates, polyoxyethyleneglycol hydroxystearates and polyoxyethylene sorbitan fatty acid esters.
4. The composition according to claim 3, wherein the non-ionic surfactant is a polyoxyethyleneglycol 12-hydroxystearate.
5. The composition according to claim 4, wherein the non-ionic surfactant is polyoxyethyleneglycol 660 12-hydroxystearate.
6. The composition according to claim 3, wherein the non-ionic surfactant is polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80.
7. The composition according to any previous claim, wherein the glucocorticosteroid is selected from the group consisting of mometasone furoate, beclomethasone dipropionate, fluticasone propionate, glucocorticosteroids with an asymmetric acetal structure involving a 16╬▒,17╬▒-butylidenedioxy group, and pharmaceutically acceptable solvates, esters, acetals and salts, and solvates of any of these.
8. The composition according to claim 7, wherein the glucocorticosteroid is rofleponide palmitate.
9. A composition according to any previous claim, wherein the amount of the surfac- tant is less than 5 % (w/w) of the total composition weight, preferably less than 3 % (w/w), more preferably less than 1 % (w/w) of the total composition weight.
10. A composition according to any previous claim, wherein the composition further comprises one or more pharmaceutically acceptable additives selected from the group consisting of antioxidants, isotonicity modifying agents, pH modifiers, complexing agents and viscosity regulating agents.
1 1. A composition according to claim 10, wherein the isotonicity modifying agent is glucose.
12. A composition according to claim 10, wherein the antioxidant is selected from the group consisting of tocopherols, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT) and ascorbic acid.
13. A process for the preparation of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, the process comprising the steps of: a) dissolving the glucocorticosteroid in the surfactant; and b) adding the aqueous medium to the solution from step a) and stirring the solution.
14. The process according to claim 13, wherein the surfactant is a non-ionic surfactant.
15. The process according to claims 14, wherein said non-ionic surfactant is selected from the group consisting of poloxamers, polyoxyethylene alkyl ethers, polyoxyethylene- stearates, polyoxyethyleneglycol hydroxystearates and polyoxyethylene sorbitan fatty acid esters.
16. The process according to claim 15, wherein the non-ionic surfactant is apolyoxy- ethyleneglycol 12-hydroxystearate.
17. The process according to claim 16, wherein the non-ionic surfactant is polyoxyethyleneglycol 660 12-hydroxystearate.
18. The process according to claim 15, wherein the polyoxyethylene sorbitan fatty acid ester is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80.
19. The process according to any one of claims 13-18, wherein the glucocorticosteroid is selected from the group consisting of mometasone furoate, beclomethasone dipropionate, fluticasone propionate, glucocorticosteroids with an asymmetric acetal structure involving a 16╬▒,17╬▒-butylidenedioxy group, and pharmaceutically acceptable solvates, esters, acetals and salts, and solvates of any of these.
20. The process according to claim 19, wherein the glucocorticosteroid is rofleponide palmitate.
21. The process according to any one of claims 13-20, wherein the amount of the surfactant is less than 5 % (w/w) of the total composition weight, preferably less than 3 % (w/w), more preferably less than 1 % (w/w) of the total composition weight.
22. The process according to any of the claims 13-21, wherein the composition further comprises one or more pharmaceutically acceptable additives selected from the group consisting of antioxidants, isotonicity modifying agents, pH modifiers, complexing agents and viscosity regulating agents.
23. The process according to claim 22, comprising dissolving glucose in an isotonic amount in the aqueous medium before adding the aqueous medium to the solution from step a).
24. Use of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, for the manufacture of a medicament for treating allergic and/or inflammatory diseases in the respiratory tract.
25. Use according to claim 24, wherein the daily dose of the glucocorticosteroid lies in the range of from 10 to 2400 ╬╝g, preferably from 10 to 1600 ╬╝g.
26. Use of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, for the manufacture of a medicament for treating intestinal diseases.
27. Use according to claim 26, wherein the daily dose of the glucocorticosteroid lies in the range of from 400 to 4000 ╬╝g, preferably from 800 to 3000 ╬╝g.
28. Use according to any one of claims 24 to 27, wherein the composition is as defined in anyone of claims 2-12.
29. A method for treatment of allergic and/or inflammatory diseases in the respiratory tract of a mammal comprising administering to the mammal in need of such a treatment a therapeutically effective amount of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant.
30. A method for treatment of intestinal diseases in a mammal, comprising administering to the mammal in need of such a treatment a therapeutically effective amount of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant.
31. A method for treatment according to claim 29 or 30, wherein the composition is as defined in anyone of claims 2-12.
EP98964662A 1997-12-22 1998-12-22 Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant Withdrawn EP1043973A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9704833A SE9704833D0 (en) 1997-12-22 1997-12-22 New formulation
SE9704833 1997-12-22
PCT/SE1998/002426 WO1999032089A1 (en) 1997-12-22 1998-12-22 Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant

Publications (1)

Publication Number Publication Date
EP1043973A1 true EP1043973A1 (en) 2000-10-18

Family

ID=20409536

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98964662A Withdrawn EP1043973A1 (en) 1997-12-22 1998-12-22 Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant

Country Status (20)

Country Link
EP (1) EP1043973A1 (en)
JP (1) JP2001526210A (en)
KR (1) KR20010024789A (en)
CN (1) CN1283106A (en)
AR (1) AR017220A1 (en)
AU (1) AU1993599A (en)
BR (1) BR9813811A (en)
CA (1) CA2315782A1 (en)
EE (1) EE200000388A (en)
HU (1) HUP0102365A3 (en)
ID (1) ID26945A (en)
IL (1) IL136880A0 (en)
NO (1) NO20003220L (en)
NZ (1) NZ505073A (en)
PL (1) PL341361A1 (en)
SE (1) SE9704833D0 (en)
SK (1) SK9532000A3 (en)
TR (1) TR200001977T2 (en)
WO (1) WO1999032089A1 (en)
ZA (1) ZA9811461B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902674D0 (en) * 1999-07-12 1999-07-12 Astra Ab New composition
SE0000332D0 (en) * 2000-01-31 2000-01-31 Astrazeneca Ab New use
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SE0100901D0 (en) * 2001-03-15 2001-03-15 Astrazeneca Ab New composition
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1661556A4 (en) * 2003-08-20 2010-05-19 Ajinomoto Kk Medicinal preparation having improved dissolution properties
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CN100579510C (en) * 2006-04-13 2010-01-13 新疆维吾尔自治区包虫病临床研究所 Precursor micelle preparation and its production process
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
WO2009064460A2 (en) 2007-11-13 2009-05-22 Meritage Pharma, Inc. Gastrointestinal delivery systems
CN102149368B (en) * 2008-09-12 2017-02-08 重症药物有限公司 Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
CN101982168B (en) * 2010-11-02 2012-05-23 山东大学 Quercetin nano-micelle preparation and preparation method thereof
CN102793678B (en) * 2011-05-26 2017-06-30 邓世明 A kind of preparation method of the Docetaxel injection without tween
DE102011108948A1 (en) * 2011-07-29 2013-01-31 Achim Göpferich Aqueous, colloidal solutions of lipophilic substances, in particular drug solutions
JP5456802B2 (en) * 2012-01-23 2014-04-02 株式会社Ｃａｃ Cell migration promoter and transdermal absorbent for wound treatment
US10596115B2 (en) * 2013-07-17 2020-03-24 Council Of Scientific & Industrial Research Pharmaceutical composition for the treatment of diminution of bone tissue
KR102086316B1 (en) * 2019-09-09 2020-03-09 한국콜마주식회사 Cosmetic composition having excellent percutaneous absorption property

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
AR002009A1 (en) * 1994-12-22 1998-01-07 Astra Ab PHARMACEUTICAL COMPOSITION, PROCEDURE FOR THE MANUFACTURE OF A PROLIPOSOMA POWDER AS USED IN SUCH COMPOSITION, PROCEDURE FOR LAMANUFACTURE OF SUCH COMPOSITION, USE OF SUCH PHARMACEUTICAL COMPOSITION IN THE MANUFACTURE OF A DISPOSAL MEDICINAL PRODUCT.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9932089A1 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10912783B2 (en) 2015-07-23 2021-02-09 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10532059B2 (en) 2016-04-01 2020-01-14 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Also Published As

Publication number Publication date
WO1999032089A1 (en) 1999-07-01
SE9704833D0 (en) 1997-12-22
NO20003220D0 (en) 2000-06-21
HUP0102365A2 (en) 2001-11-28
EE200000388A (en) 2002-02-15
CA2315782A1 (en) 1999-07-01
BR9813811A (en) 2000-10-03
ZA9811461B (en) 1999-06-22
AU1993599A (en) 1999-07-12
NO20003220L (en) 2000-08-22
JP2001526210A (en) 2001-12-18
ID26945A (en) 2001-02-22
CN1283106A (en) 2001-02-07
NZ505073A (en) 2002-09-27
HUP0102365A3 (en) 2002-01-28
PL341361A1 (en) 2001-04-09
KR20010024789A (en) 2001-03-26
IL136880A0 (en) 2001-06-14
AR017220A1 (en) 2001-08-22
SK9532000A3 (en) 2000-11-07
TR200001977T2 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
WO1999032089A1 (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant
DE69928665T2 (en) Corticosteroids containing aqueous compositions for nasal or pulmonary delivery
US6258374B1 (en) Foam-forming pharmaceutical composition
KR100524358B1 (en) Preparation of aqueous clear solution dosage forms with bile acids
EA013351B1 (en) Pharmaceutical formulations comprising a long-acting beta-agonist for administration by dispersion
JP5001657B2 (en) Aqueous suspension of ciclesonide for nebulization
JP2006523630A (en) Nasal pharmaceutical preparation and method of use thereof
US20120022032A1 (en) Corticosteroid compositions and methods of treatments thereof
CN101757625A (en) Nasal pharmaceutical composition of cyclodextrin inclusion cortin and H1 receptor antagonist
WO1996010991A1 (en) Pharmaceutical composition containing derivatives of sex hormones
US8466134B1 (en) Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US20210379080A1 (en) Intranasal Formulation
US11642309B2 (en) Aqueous compositions comprising bilastine and mometasone
MXPA00006161A (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant
CZ20002298A3 (en) Pharmaceutical preparation containing micelles in aqueous medium and process for preparing thereof
KR20060012030A (en) Transnasal microemulsions containing diazepam
JP3470131B2 (en) Long-acting nasal drops
WO2023102363A1 (en) Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
WO2024079676A1 (en) Novel nasal spray assembling process
EA037259B1 (en) Use of a fixed dose pharmaceutical composition comprising mometasone and azelastine in treating allergic rhinitis and method of treating allergic rhinitis
CN1750810A (en) A low dose corticosteroid composition
RU2000116013A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MICELS WHICH CONTAIN A LIPOPHILIC GLUCOCORTICOSTEROID AND ONLY ONE SURFACE-ACTIVE SUBSTANCE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000724

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 20000724;LV PAYMENT 20000724;MK PAYMENT 20000724;RO PAYMENT 20000724;SI PAYMENT 20000724

17Q First examination report despatched

Effective date: 20020402

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030701

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1030888

Country of ref document: HK